Europe Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Parenteral and Oral), By Drug Type (Analgesics, DMARDs, Corticosteroids), By Country and Growth Forecast, 2023 - 2029

The Europe Musculoskeletal Disorders Drugs Market would witness market growth of 3.6% CAGR during the forecast period (2023-2029).

Various factors, such as an aging population, sedentary behaviors, obesity, and a higher incidence of work-related injuries, contribute to the rise in incidences and prevalence of musculoskeletal disorders. Consequently, the increase in the number of cases of musculoskeletal disorders has raised the need for treatment options and supported the growth of the market. In addition, an increase in patient awareness regarding the significance of early diagnosis and treatment of MSDs drives the demand. Increased product launches by key participants are expected to impact market growth positively.

The need for musculoskeletal disorder drugs is not limited to developed countries; it is also observed in developing countries, which contributes to the expansion of the market share. In addition, a rise in promotional efforts by manufacturers is anticipated to accelerate the acceptance of such drugs in the near future. Also, the aging population is especially vulnerable to musculoskeletal disorders such as rheumatoid arthritis, osteoarthritis, and osteoporosis. The growing population of senior people has led to a growth in the need for medications to treat musculoskeletal disorders, which in turn has propelled the market for such medications forward.

An investigation conducted by the Ministry of Health in 2015 found that 64.5 percent of Italians over 11 have ingested alcohol at least once. Furthermore, there was additional proof of regular alcohol use between the ages of 11 and 24 that didn't involve meals. It is projected that as more people drink alcohol, adversely affecting numerous organ systems and tissues, including skeletal muscle, the prevalence of musculoskeletal problems will rise. Thus, the need for treatment drugs will rise, driving the market's growth in Europe.

The Germany market dominated the Europe Musculoskeletal Disorders Drugs Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $7,381.3 Million by 2029. The UK market is experiencing a CAGR of 2.7% during (2023 - 2029). Additionally, The France market would exhibit a CAGR of 4.4% during (2023 - 2029).

Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Drug Type, the market is segmented into Analgesics, DMARDs, Corticosteroids and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Worldwide Musculoskeletal Disorders Drugs Market is Projected to reach USD 109.4 Billion by 2029, at a CAGR of 4.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

• Drug Stores & Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Route of Administration

• Parenteral
• Oral

By Drug Type

• Analgesics
• DMARDs
• Corticosteroids
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• AbbVie, Inc.
• Amgen, Inc.
• Eli Lilly And Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Musculoskeletal Disorders Drugs Market, by Distribution Channel
1.4.2 Europe Musculoskeletal Disorders Drugs Market, by Route of Administration
1.4.3 Europe Musculoskeletal Disorders Drugs Market, by Drug Type
1.4.4 Europe Musculoskeletal Disorders Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Geographical Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Europe Musculoskeletal Disorders Drugs Market by Distribution Channel
4.1 Europe Drug Stores & Retail Pharmacies Market by Country
4.2 Europe Hospital Pharmacies Market by Country
4.3 Europe Online Providers Market by Country

Chapter 5. Europe Musculoskeletal Disorders Drugs Market by Route of Administration
5.1 Europe Parenteral Market by Country
5.2 Europe Oral Market by Country

Chapter 6. Europe Musculoskeletal Disorders Drugs Market by Drug Type
6.1 Europe Analgesics Market by Country
6.2 Europe DMARDs Market by Country
6.3 Europe Corticosteroids Market by Country
6.4 Europe Others Market by Country

Chapter 7. Europe Musculoskeletal Disorders Drugs Market by Country
7.1 Germany Musculoskeletal Disorders Drugs Market
7.1.1 Germany Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.2 Germany Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.3 Germany Musculoskeletal Disorders Drugs Market by Drug Type
7.2 UK Musculoskeletal Disorders Drugs Market
7.2.1 UK Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.2 UK Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.3 UK Musculoskeletal Disorders Drugs Market by Drug Type
7.3 France Musculoskeletal Disorders Drugs Market
7.3.1 France Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.2 France Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.3 France Musculoskeletal Disorders Drugs Market by Drug Type
7.4 Russia Musculoskeletal Disorders Drugs Market
7.4.1 Russia Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.2 Russia Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.3 Russia Musculoskeletal Disorders Drugs Market by Drug Type
7.5 Spain Musculoskeletal Disorders Drugs Market
7.5.1 Spain Musculoskeletal Disorders Drugs Market by Distribution Channel
7.5.2 Spain Musculoskeletal Disorders Drugs Market by Route of Administration
7.5.3 Spain Musculoskeletal Disorders Drugs Market by Drug Type
7.6 Italy Musculoskeletal Disorders Drugs Market
7.6.1 Italy Musculoskeletal Disorders Drugs Market by Distribution Channel
7.6.2 Italy Musculoskeletal Disorders Drugs Market by Route of Administration
7.6.3 Italy Musculoskeletal Disorders Drugs Market by Drug Type
7.7 Rest of Europe Musculoskeletal Disorders Drugs Market
7.7.1 Rest of Europe Musculoskeletal Disorders Drugs Market by Distribution Channel
7.7.2 Rest of Europe Musculoskeletal Disorders Drugs Market by Route of Administration
7.7.3 Rest of Europe Musculoskeletal Disorders Drugs Market by Drug Type

Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.6 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals and Trials:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Geographical Expansions:
8.4 UCB S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.6 Eli Lilly And Company
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.7 F. Hoffmann-La Roche Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 Merck & Co., Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.9 Novartis AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses

TABLE 1 Europe Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 2 Europe Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Musculoskeletal Disorders Drugs Market
TABLE 4 geographical expansions – Musculoskeletal Disorders Drugs Market
TABLE 5 Acquisition and Mergers– Musculoskeletal Disorders Drugs Market
TABLE 6 Approvals and trials – Musculoskeletal Disorders Drugs Market
TABLE 7 Europe Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 Europe Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 9 Europe Drug Stores & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Drug Stores & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 11 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 13 Europe Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 15 Europe Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 16 Europe Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 17 Europe Parenteral Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Parenteral Market by Country, 2023 - 2029, USD Million
TABLE 19 Europe Oral Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Oral Market by Country, 2023 - 2029, USD Million
TABLE 21 Europe Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 22 Europe Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 23 Europe Analgesics Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Analgesics Market by Country, 2023 - 2029, USD Million
TABLE 25 Europe DMARDs Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe DMARDs Market by Country, 2023 - 2029, USD Million
TABLE 27 Europe Corticosteroids Market by Country, 2019 - 2022, USD Million
TABLE 28 Europe Corticosteroids Market by Country, 2023 - 2029, USD Million
TABLE 29 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 30 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 31 Europe Musculoskeletal Disorders Drugs Market by Country, 2019 - 2022, USD Million
TABLE 32 Europe Musculoskeletal Disorders Drugs Market by Country, 2023 - 2029, USD Million
TABLE 33 Germany Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 34 Germany Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 35 Germany Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 36 Germany Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 37 Germany Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 38 Germany Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 39 Germany Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 40 Germany Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 41 UK Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 42 UK Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 43 UK Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 44 UK Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 45 UK Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 46 UK Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 47 UK Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 48 UK Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 49 France Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 50 France Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 51 France Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 52 France Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 53 France Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 54 France Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 55 France Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 56 France Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 57 Russia Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 58 Russia Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 59 Russia Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 Russia Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 61 Russia Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 62 Russia Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 63 Russia Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 64 Russia Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 65 Spain Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 66 Spain Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 67 Spain Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 68 Spain Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 69 Spain Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 70 Spain Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 71 Spain Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 72 Spain Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 73 Italy Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 74 Italy Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 75 Italy Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 76 Italy Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 77 Italy Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 78 Italy Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 79 Italy Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 80 Italy Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 81 Rest of Europe Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 82 Rest of Europe Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 83 Rest of Europe Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 84 Rest of Europe Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 85 Rest of Europe Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 86 Rest of Europe Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 87 Rest of Europe Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 88 Rest of Europe Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 89 Key information –Johnson & Johnson
TABLE 90 Key Information – Pfizer, Inc.
TABLE 91 Key information – AbbVie, Inc.
TABLE 92 Key Information – UCB S.A.
TABLE 93 Key Information – Amgen, Inc.
TABLE 94 Key Information – Eli Lilly And Company
TABLE 95 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 96 KEY INFORMATION - Merck & Co., Inc.
TABLE 97 Key Information – Novartis AG
TABLE 98 Key Information – Teva Pharmaceuticals Industries Ltd.

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Europe Musculoskeletal Disorders Drugs Market Share by Distribution Channel, 2022
FIG 5 Europe Musculoskeletal Disorders Drugs Market Share by Distribution Channel, 2029
FIG 6 Europe Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2029, USD Million
FIG 7 Europe Musculoskeletal Disorders Drugs Market Share by Route of Administration, 2022
FIG 8 Europe Musculoskeletal Disorders Drugs Market Share by Route of Administration, 2029
FIG 9 Europe Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2029, USD Million
FIG 10 Europe Musculoskeletal Disorders Drugs Market Share by Drug Type, 2022
FIG 11 Europe Musculoskeletal Disorders Drugs Market Share by Drug Type, 2029
FIG 12 Europe Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2029, USD Million
FIG 13 Europe Musculoskeletal Disorders Drugs Market Share by Country, 2022
FIG 14 Europe Musculoskeletal Disorders Drugs Market Share by Country, 2029
FIG 15 Europe Musculoskeletal Disorders Drugs Market by Country, 2019 - 2029, USD Million
FIG 16 SWOT analysis: Johnson & Johnson
FIG 17 Recent strategies and developments: Pfizer, Inc.
FIG 18 Recent strategies and developments: AbbVie, Inc.